Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Kazuaki Ikejiri"'
Publikováno v:
Kidney International Reports, Vol 7, Iss 2, Pp 177-188 (2022)
Introduction: Simplified, but effective, hyperphosphatemia treatments with novel mechanisms of action, tolerable safety profiles, and low pill burden are needed for patients undergoing hemodialysis. Tenapanor is a calcium (Ca)-free, nonmetal, nonpoly
Externí odkaz:
https://doaj.org/article/48210c61531d4a239a5482b91c800fc1
Publikováno v:
Kidney International Reports, Vol 7, Iss 2, Pp 177-188 (2022)
Introduction: Simplified, but effective, hyperphosphatemia treatments with novel mechanisms of action, tolerable safety profiles, and low pill burden are needed for patients undergoing hemodialysis. Tenapanor is a calcium (Ca)-free, nonmetal, nonpoly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c96bb8ea45901407cee80238b234079
http://www.sciencedirect.com/science/article/pii/S246802492101514X
http://www.sciencedirect.com/science/article/pii/S246802492101514X
Publikováno v:
Kidney International Reports
Introduction The current management of hyperphosphatemia with phosphate binders is associated with insufficient phosphorus control and a significant pill burden. Tenapanor, a first-in-class, phosphate absorption inhibitor, is expected to control phos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89a40fbffc8a91966e4aa33dc3f4ae66
https://doi.org/10.1016/j.ekir.2021.06.030
https://doi.org/10.1016/j.ekir.2021.06.030
Autor:
Tadao Akizawa, Takashi Shigematsu, Masafumi Fukagawa, Hironori Kanda, Kazuaki Ikejiri, Yotaro Une
Publikováno v:
Am J Nephrol
Introduction: Phosphate binders are used to treat hyperphosphatemia. Some patients have inappropriately controlled serum phosphorus levels, which may occur for many reasons, including a high pill burden and adverse events (AEs). Tenapanor selectively
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4f4b56832d0962773a56e91aa27415d
https://doi.org/10.1159/000516156
https://doi.org/10.1159/000516156
Publikováno v:
Kidney International Reports. 7:1725-1726
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43171e76fa586a49c4fe40a7949a8ad5
https://doi.org/10.1016/j.ekir.2022.05.023
https://doi.org/10.1016/j.ekir.2022.05.023
Publikováno v:
Therapeutic Apheresis and Dialysis
Patients with chronic kidney disease often develop secondary hyperparathyroidism (SHPT), marked by high levels of circulating parathyroid hormone (PTH) and increased risk of morbidity and mortality. Patients with SHPT are treated with a therapeutic c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ccc4b12e41f9ae48d2c4922cfa90d62
http://europepmc.org/articles/PMC7317959
http://europepmc.org/articles/PMC7317959
Autor:
Kazuya Maeda, Kazuaki Ikejiri, Hiroyuki Kusuhara, Kota Toshimoto, Tomohisa Nakada, Takashi Yoshikado, Yuichi Sugiyama
Publikováno v:
Drug Metabolism and Disposition. 45:779-789
It is essential to estimate concentrations of unbound drugs inside the hepatocytes to predict hepatic clearance, efficacy, and toxicity of the drugs. The present study was undertaken to compare predictability of the unbound hepatocyte-to-medium conce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82a44c0c92cb4c7630906e56324b73fc
https://doi.org/10.1124/dmd.116.074823
https://doi.org/10.1124/dmd.116.074823
Autor:
Hiroyuki Kusuhara, Masahiro Ono, Hideo Saji, Yusuke Yagi, Yuichi Sugiyama, Junichi Takano, Kazuya Maeda, Shinya Kagawa, Hiroyuki Kimura, Kazuaki Ikejiri, Kenji Arimitsu
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 59:565-575
Pitavastatin is an antihyperlipidemic agent, a potent inhibitor of 3-hydroxymethyl-glutaryl-CoA reductase, which is selectively taken up into the liver mainly via hepatic organic anion transporting polypeptide 1B1 (OATP1B1). OATP1B1 can accept a vari
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44f384daa635efe924b555265f842d34
https://doi.org/10.1002/jlcr.3464
https://doi.org/10.1002/jlcr.3464
Autor:
Kazuya Maeda, Kazuaki Ikejiri, Kenta Yoshida, Yoshihisa Shitara, Toshiharu Horie, Yuichi Sugiyama
Publikováno v:
Biopharmaceutics & Drug Disposition. 34:45-78
Organic anion transporting polypeptide (OATP) family transporters accept a number of drugs and are increasingly being recognized as important factors in governing drug and metabolite pharmacokinetics. OATP1B1 and OATP1B3 play an important role in hep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::63ea80eaea44dae4c2fd8f81ff1fc801
https://doi.org/10.1002/bdd.1823
https://doi.org/10.1002/bdd.1823
Autor:
Tsukasa Uno, Yuichi Sugiyama, Kenta Yoshida, Kayoko Kanamitsu, Miyuu Yokochi, Masatomo Miura, Norio Yasui-Furukori, Yumiko Akamine, Shinya Fukizawa, Kazuaki Ikejiri, Hiroyuki Kusuhara
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 41(1)
The effect of rifampicin on the pharmacokinetics of fexofenadine enantiomers was examined in healthy subjects who received fexofenadine alone or with single or multiple doses of rifampicin (600 mg). A single coadministered dose of rifampicin signific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c1982189d1d6b3863f9ea46dc1fb75e
https://pubmed.ncbi.nlm.nih.gov/23115085
https://pubmed.ncbi.nlm.nih.gov/23115085